Ensysce Biosciences responds to recent shareholder inquiries
PremiumThe FlyEnsysce Biosciences responds to recent shareholder inquiries
1M ago
Ensysce Biosciences receives Nasdaq notice
Premium
The Fly
Ensysce Biosciences receives Nasdaq notice
1M ago
Ensysce Biosciences to present at upcoming meetings
Premium
The Fly
Ensysce Biosciences to present at upcoming meetings
2M ago
Ensysce Biosciences receives $14M NIH grant for novel opioid development
PremiumThe FlyEnsysce Biosciences receives $14M NIH grant for novel opioid development
2M ago
ENSC Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ENSC Upcoming Earnings Report: What to Expect?
3M ago
Ensysce Biosciences ready to commence PF614 Phase 3 trial in 2024
Premium
The Fly
Ensysce Biosciences ready to commence PF614 Phase 3 trial in 2024
4M ago
Ensysce Biosciences regains compliance with Nasdaq
PremiumThe FlyEnsysce Biosciences regains compliance with Nasdaq
6M ago
Ensysce Biosciences renews collaboration with Quotient Sciences
Premium
The Fly
Ensysce Biosciences renews collaboration with Quotient Sciences
6M ago
Ensysce Biosciences reports Q1 EPS (55c) vs. ($2.08) last year
Premium
The Fly
Ensysce Biosciences reports Q1 EPS (55c) vs. ($2.08) last year
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100